The Myriad Neuroscience Scientific Advisory Board guides continuing innovation of GeneSight® technology.
Boadie W. Dunlop, M.D.
Dr. Boadie Dunlop is Associate Professor and Director of the Mood and Anxiety Disorders Program (MAP) at Emory University. He graduated from Mayo Medical School in 1997, completed his Residency in Psychiatry at Emory in 2001 and became Director of MAP in 2006. His clinical research program is focused on the neurobiology, psychopharmacology, and the personalized treatment of major depression, bipolar disorder, post-traumatic stress disorder, and anxiety disorders. He has served as an investigator for more than 70 clinical studies of medication and psychotherapy treatments for these conditions. His additional academic interests include clinical trial design and the ethics of clinical research. He is currently the principal investigator of two National Institute of Mental Health grants examining neuroimaging and metabolomic predictors of outcome to treatments for major depressive disorder. Dr. Dunlop has has authored one book, nine book chapters and approximately 100 research papers on mental health topics. In addition, Dr. Dunlop is active in the education of Emory’s Psychiatry residents. He serves as the course director for the Mood and Anxiety Disorders lecture series and provides supervision in psychopharmacology for Emory Psychiatry residents.
James L. Kennedy, M.D., FRCP(C), FRSC
Dr. Kennedy has training in three major areas: neuroscience, clinical psychiatry, and molecular genetics. His main research interest over the past 20 years has been the identification of susceptibility genes for psychiatric disorders. This has involved extensive hypothesis-based investigations of genetic variation in neurobiologic systems known to be involved in psychiatric disorders and addictions. Discoveries from his Neurogenetics laboratory include: (1) the role of the DRD4 gene in ADHD, one of the most consistently replicated findings in all of behavioral genetics; (2) the discovery of the role of the DRD3 gene in predicting Tardive Dyskinesia (issued US patent); (3) prediction of the serious side effect of antidepressant-induced mania associated with the S allele of the 5HTTLPR variant (issued US patent); (4) the role of glutamate system genes (SLC1A1 and GRIN2B) in Obsessive Compulsive Disorder; (5) established the feasibility of pharmacogenetic testing (IMPACT study, N = 11,000 tested) in psychiatry and primary care setting; and (6) conducted randomized controlled trials (N=450 depression, 140 schizophrenia). He has one of the most comprehensive collections of DNAs (N = 34,000) for any one institution in the world in terms of range of psychiatric disorders (N=18) and sub-phenotypes (N=50+). Dr. Kennedy has published more than 650 peer-reviewed scientific articles with over 25,000 citations, and Scopus H-index of 87. He is a member of the Royal Society of Canada, the highest academic recognition in Canada.
To learn more about Dr. Kennedy, please visit the CAMH website.
Learn more about Dr. Kennedy’s research at PubMed.
Lawrence J. Lesko, Ph.D., FCP
Dr. Lawrence J. Lesko is currently Emeritus Professor and Founding Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida College of Pharmacy at Lake Nona (Orlando). He started the Center in 2011 and served as its full-time Director for 5 years. He continues part-time in the Center and officially retired in February 2018. He now serves as a consultant to pharmaceutical companies and healthcare organizations. Dr. Lesko, starting in 1995, became the first director of the Office of Clinical Pharmacology (OCP) in the Center for Drug Evaluation and Research at the Food and Drug Administration. His tenure as Office Director was for 16 years until his retirement in 2011. At the FDA, Dr. Lesko formed a pharmacological mechanism-based drug safety assessment team to analyze the root cause of adverse drug events. This program used mechanistic approaches to understand off-target drug effects using bioinformatics strategies. He also led the advancement of precision medicine through the update of labels of previously approved drugs with new genetic information on safety, dosing and efficacy. Dr. Lesko coauthored numerous Guidance for Industry including “Clinical Pharmacogenomics: Premarketing Evaluation in Early Clinical Trials” and “Pharmacogenomics Data Submissions”. He also started a Division of Pharmacometrics (i.e., Biosimulation) that is responsible for quantitative analysis of dose response and PK-PD (biomarkers) relationships to support optimal dosing in FDA approved drug labels, and the development of drug-disease models to support clinical trial simulations in drug development. Dr. Lesko has published more than 200 peer-reviewed manuscripts and is a frequent invited national and international speaker. In 2018, Dr. Lesko received the first FDA OCP Distinguished Alumni Lectureship Award for his contributions to clinical pharmacology. He was the recipient of the 2015 Leadership Award from the International Society of Pharmacometrics, the 2015 Agilent Technologies Thought Leader Award in Integrated Systems Toxicology and the 2014 AAPS Distinction in Biomarker Research Award. In 2011, he received the Gary Neil Prize for Innovation in Drug Development from the American Society of Clinical Pharmacology and Therapeutics (ASCPT). Dr. Lesko also was honored with the Rawls Palmer Progress in Medicine award from ASCPT, the Coriell Scientific Leadership Award for Personalized Medicine, the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Award for Clinical Service, and the Nathanial B. Kwit Distinguished Service Award for Clinical Pharmacology from the American College of Clinical Pharmacology.
To learn more about Dr. Lesko, please visit University of Florida, College of Pharmacy’s website.
Learn more about Dr. Lesko’s research at PubMed.
Andrew Nierenberg, M.D.
Dr. Nierenberg holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Massachusetts General Hospital, and is the Director of the Dauten Family Center for Bipolar Treatment Innovation, and Associate Director of the Depression Clinical and Research Program, as well as the Director of the Center for Clinical Research Education at MGH. He has published over 470 papers and has been listed among the Best Doctors in North America for the treatment of mood and anxiety disorders continuously since 1994. He received the Depression Bipolar Support Alliance Gerald L. Klerman Young and Senior Investigator Awards, the Brain and Behavior Foundation Colvin Prize for outstanding achievement in mood disorders research, and was listed among the World’s Most Influential Scientific Minds 2014, 2015, 2016, and 2017 by Thompson Reuters for being in the top 1% of literature citations in psychiatry/psychology worldwide. His primary interests are novel treatments for people with mood disorders. Dr. Nierenberg lectures nationally and internationally, teaches and supervises clinicians and researchers, maintains an active clinical practice, conducts clinical trials, and is on the editorial boards of multiple psychiatric journals, including Editor in Chief of Psychiatric Annals and Deputy Editor, Depression and Anxiety.